Last reviewed · How we verify
NCT06949267
A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
EARLY_PHASE1 trial testing iMSC in Acute Graft-versus-Host Disease in 56 participants. Not yet recruiting.
30 September 2026
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 56 |
| Start date | 1 June 2025 |
| Primary completion | 30 September 2026 |
| Estimated completion | 31 March 2028 |
Drugs / interventions tested
- iMSC — full drug profile →
- conventional aGVHD prophylaxis
Conditions studied
- Acute Graft-versus-Host Disease — all drugs for Acute Graft-versus-Host Disease →
Sponsor
Ruijin Hospital
Who can join
Adults 14 to 70, any sex, with Acute Graft-versus-Host Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An open-label, randomized, controlled clinical trial to explore the efficacy and safety of iMSC in preventing the development of acute graft-versus-host disease of degree III-IV in patients after allogeneic hematopoietic stem cell transplantation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06949267
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of iMSC
Trials testing the same drug.
- NCT06321198 — A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD · NA · recruiting
Other recruiting trials for Acute Graft-versus-Host Disease
Currently open trials in the same condition.
- NCT06880419 — Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model · Phase 2 · recruiting
- NCT06750133 — Universal CNK-UT Therapy for Refractory aGVHD · Phase 1 · recruiting
- NCT06708507 — Tissue-resident Immune Cell Subsets in aGVHD · recruiting
- NCT07070674 — A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD. · Phase 1 · recruiting
- NCT06394895 — Donor Neutrophil Subsets to Predict the Risk of aGVHD · active not recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06949267 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 29 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06949267.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing